newsfilter
← Latest News
GlobeNewswire·

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data